PHAT Straddle Strategy

PHAT (Phathom Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

PHAT (Phathom Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.00B, a beta of 0.57 versus the broader market, a 52-week range of 3.1-18.31, average daily share volume of 1.2M, a public-listing history dating back to 2019, approximately 427 full-time employees. These structural characteristics shape how PHAT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.57 indicates PHAT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a straddle on PHAT?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current PHAT snapshot

As of May 15, 2026, spot at $12.00, ATM IV 106.80%, IV rank 22.41%, expected move 30.62%. The straddle on PHAT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this straddle structure on PHAT specifically: PHAT IV at 106.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a PHAT straddle, with a market-implied 1-standard-deviation move of approximately 30.62% (roughly $3.67 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PHAT expiries trade a higher absolute premium for lower per-day decay. Position sizing on PHAT should anchor to the underlying notional of $12.00 per share and to the trader's directional view on PHAT stock.

PHAT straddle setup

The PHAT straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PHAT near $12.00, the first option leg uses a $12.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PHAT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PHAT shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$12.00	N/A
Buy 1	Put	$12.00	N/A

PHAT straddle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

PHAT straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on PHAT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use straddle on PHAT

Straddles on PHAT are pure-volatility plays that profit from large moves in either direction; traders typically buy PHAT straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

PHAT thesis for this straddle

The market-implied 1-standard-deviation range for PHAT extends from approximately $8.33 on the downside to $15.67 on the upside. A PHAT long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current PHAT IV rank near 22.41% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PHAT at 106.80%. As a Healthcare name, PHAT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PHAT-specific events.

PHAT straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PHAT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PHAT alongside the broader basket even when PHAT-specific fundamentals are unchanged. Always rebuild the position from current PHAT chain quotes before placing a trade.

Frequently asked questions

What is a straddle on PHAT?: A straddle on PHAT is the straddle strategy applied to PHAT (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With PHAT stock trading near $12.00, the strikes shown on this page are snapped to the nearest listed PHAT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are PHAT straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the PHAT straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 106.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a PHAT straddle?: The breakeven for the PHAT straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PHAT market-implied 1-standard-deviation expected move is approximately 30.62%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on PHAT?: Straddles on PHAT are pure-volatility plays that profit from large moves in either direction; traders typically buy PHAT straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current PHAT implied volatility affect this straddle?: PHAT ATM IV is at 106.80% with IV rank near 22.41%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.